Shore Capital Keeps The “Hold” Rating They’ve had for AstraZeneca PLC (LON:AZN) Shares

September 14, 2018 - By Benjamin Allen

AstraZeneca PLC (LON:AZN) Logo

AstraZeneca PLC (LON:AZN) Rating Reaffirmed

The rating of AstraZeneca PLC (LON:AZN) shares were restate by stock research analysts at Shore Capital. This was revealed to investors in a note on Friday morning.

AstraZeneca PLC (LON:AZN) Ratings Coverage

Among 14 analysts covering AstraZeneca PLC (LON:AZN), 9 have Buy rating, 0 Sell and 5 Hold. Therefore 64% are positive. AstraZeneca PLC has GBX 6500 highest and GBX 62 lowest target. GBX 5897.21’s average target is 4.91% above currents GBX 5621 stock price. AstraZeneca PLC had 66 analyst reports since March 19, 2018 according to SRatingsIntel. The rating was maintained by Shore Capital on Thursday, April 19 with “Hold”. The firm has “Hold” rating given on Tuesday, April 24 by Shore Capital. Shore Capital maintained the shares of AZN in report on Thursday, August 30 with “Hold” rating. On Tuesday, July 17 the stock rating was maintained by Deutsche Bank with “Buy”. Liberum Capital maintained AstraZeneca PLC (LON:AZN) on Friday, August 31 with “Hold” rating. Kepler Cheuvreux maintained the stock with “Buy” rating in Friday, September 7 report. Liberum Capital maintained the stock with “Hold” rating in Tuesday, April 24 report. Jefferies upgraded AstraZeneca PLC (LON:AZN) on Monday, March 19 to “Buy” rating. The firm earned “Hold” rating on Tuesday, April 3 by Shore Capital. Shore Capital maintained AstraZeneca PLC (LON:AZN) on Wednesday, August 15 with “Hold” rating.

The stock decreased 0.16% or GBX 9 during the last trading session, reaching GBX 5621. About 942,665 shares traded. AstraZeneca PLC (LON:AZN) has 0.00% since September 14, 2017 and is . It has underperformed by 15.62% the S&P500.

Analysts await AstraZeneca PLC (LON:AZN) to report earnings on November, 8. They expect $0.44 earnings per share, down 60.71 % or $0.68 from last year’s $1.12 per share. AZN’s profit will be $5.57M for 3193.75 P/E if the $0.44 EPS becomes a reality. After $0.69 actual earnings per share reported by AstraZeneca PLC for the previous quarter, Wall Street now forecasts -36.23 % negative EPS growth.

AstraZeneca PLC develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of 71.21 billion GBP. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 26.64 P/E ratio. The company??s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.